The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 25 November 2008, www.theannals.com, DOI 10.1345/aph.1L255.
 The Annals of Pharmacotherapy: Vol. 42, No. 12, pp. 1737-1748. DOI 10.1345/aph.1L255
© 2008 Harvey Whitney Books Company.
This Article
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wong, C.-M.
Right arrow Articles by Chan, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wong, C.-M.
Right arrow Articles by Chan, A.

ONCOLOGY

Clinically Significant Drug-Drug Interactions Between Oral Anticancer Agents and Nonanticancer Agents: Profiling and Comparison of Two Drug Compendia

Chen-May Wong

Pharmacy Student, Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore

Yu Ko, PhD

Research Fellow, Department of Pharmacy, Faculty of Science, National University of Singapore

Alexandre Chan, PharmD BCPS BCOP

Assistant Professor, Department of Pharmacy, Faculty of Science, National University of Singapore; Clinical Pharmacist, Department of Pharmacy, National Cancer Centre, Singapore

Reprints: Dr. Chan, Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4, 16 Science Dr. 4, Singapore 117543, fax 65 6779 1554, phaac{at}nus.edu.sg.

BACKGROUND: Use of oral anticancer agents is gaining wide acceptance in the treatment of cancer. However, patients receiving oral therapy are at high risk for drug-drug interactions (DDIs).

OBJECTIVE: To create a drug profile for each clinically significant DDI involving selected oral anticancer agents and evaluate the agreement between 2 commonly used DDI compendia: Drug Interaction Facts (DIF) 2008 and Micromedex DRUGDEX.

METHODS: DDI profiles were developed based on primary and tertiary literature reviews. DIF 2008 and Micromedex DRUGDEX were compared to assess the consistency of listings, severity, and scientific evidence ratings of DDIs involving the oral anticancer agents that were selected. The Spearman correlation test was used to assess the correlation of the severity ratings between the 2 compendia.

RESULTS: A total of 184 DDIs were identified. A DDI profile was created for 40 of these that met the predetermined criteria for clinically significant interactions. The comparative assessment showed inconsistency in DDI listings (15.2% of those identified were listed in DIF only and 46.7% were listed in Micromedex only), severity ratings (Spearman correlation coefficient 0.49), and scientific evidence ratings (disagreement 25.8%).

CONCLUSIONS: The discrepancies in DDI listing and rating systems between the compendia evaluated here reflect the need for more studies to standardize the definitions and classifications of DDIs.

Key Words: drug compendia, drug-drug interactions, drug information

Published Online, November 25, 2008. www.theannals.com, DOI 10.1345/aph.1L255




homecopy help contact us subscription past issues search current issue
Copyright © 2008 by Harvey Whitney Books Company.